Stocks in play: Eupraxia Pharmaceuticals Inc.
Announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology European Congress of Rheumatology 2024 (the "Meeting"). The EULAR Meeting is being held in Vienna, Austria from June 12-15. Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading up $0.01 at $3.70.
Read:
Big Tech Invests in Global AI Data Centers: Major Developments Announced
Global Food Security Crisis: How Agritech Innovations are Rising to the Challenge
IEA Warns of Copper Supply Deficit: New Mines Needed to Meet Surging Demand
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032
Agricultural Biotechnology Market to Hit $232 Billion by 2032, Driven by Technological Advancements